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A lthough viruses have been used extensively to treat cancer by direct injection or by the administration of viral oncolysates to induce tumor-specific immune responses, few successful instances of oncolysis in vivo have been reported. 1 Two major obstacles that have been identified are the lack of specificity that damages host tissues and leads to viremia in some immunosuppressed patients and the incomplete tumor destruction attributable to an immune response that halts the virus spread. 2 To achieve selective replication in tumor cells, viral genes that are dispensable for propagation in certain tumor cells have been deleted in herpes simplex virus type 1 and in adenovirus (Ad) type 5 (Ad5). 3, 4 Alternatively, adenoviral replication has also been restricted to tumor cells by placing viral genes under the control of tumor-specific promoters such as the ␣-fetoprotein (AFP) promoter or the prostate-specific antigen promoter. 5, 6 In a different approach, Ad has been used extensively as a vector for the delivery of nonviral genes in cancer gene therapy. Tumor-specific promoters have also been used in this approach to control the expression of the therapeutic gene. [7] [8] [9] The major hurdle with this approach has been to achieve transduction of enough cells to completely eliminate the tumors, especially in cases in which the bystander effect over the nontransduced cells is limited. The effect of tumor-suppressor genes, immunomodulatory genes, or cytotoxic genes could synergize with the oncolytic effect of a replicationcompetent vector. Reciprocally, the outcome of the viral oncolysis could be affected by foreign genes that are able to change the immune response to the replicating vector. 10, 11 The capacity for foreign gene insertion in current replication-competent Ads is limited by the number of viral gene deletions that can be complemented by the tumor cells. This drawback increases when replication is controlled by inserting a tumor-specific promoter to drive a viral gene. In an effort to address this problem and also to palliate the safety concerns associated with viral replication, we have split the Ad genome into two complementary vectors. The genome of one of these vectors contains the adenoviral inverted terminal repeats (ITRs) for replication, the adenoviral packaging signal, and the E1 genes with E1A under the control of a 5-kilobase (kb) AFP promoter. This vector has a capacity for 30 kb of foreign DNA and propagates only in cells that express AFP when an E1-deleted vector is also present.
MATERIALS AND METHODS

Cells and cell culture
Three human hepatocarcinoma cell lines (HepG2, HuH7, and SK-Hep-1) and one non-small lung adenocarcinoma cell line (A549) were obtained from the American Type Culture Col-lection (Manassas, Va). HepG2 and HuH7 express AFP, whereas SK-Hep-1 does not. 7 The cells were maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine sera.
Construction and purification of GT5610/AdH␤
A 5.1-kb region of the human AFP promoter (GenBank no. J02693 plus M16110) containing the proximal and distal regulatory elements was amplified by polymerase chain reaction from HepG2 genomic DNA. The primers used were: Upstream, 5Ј-CTAACGCGTGCGGCCGCTgaattcttagaa-3Ј, with a nonhomologous tail (uppercase) containing MluI and NotI sites (underlined) for cloning purposes; and downstream, 5Ј-GATCGCAattggcagtggtggaagcacaat-3Ј, with a nonhomologous tail (uppercase) containing the MfeI site (underlined). In a different adenoviral vector, a similar AFP promoter region has been shown to confer specific gene expression in AFPproducing cells. 7 The polymerase chain reaction product was cloned into pCR II (Invitrogen, San Diego, Calif), and the E1 region of Ad (AflIII-AflII, Ad5 nucleotides 460-3538) was cloned downstream of this promoter. The AFP-E1 expression cassette was then subcloned into a derivative of pE5E3, an adenoviral vector containing a green fluorescent protein (GFP) expression cassette, the ITRs and packaging signal of Ad5, and albumin and AFP genomic sequences as stuffer DNA.
12 Figure 1 shows the structure of the final plasmid GT5610 linearized by the ITRs as found after viral replication. AdH␤ was constructed as described previously; 12 it is an adenoviral vector in which a ␤-galactosidase (␤-gal) expression cassette replaces the E1 region (from Ad5 nucleotides 452 to 3328) and a portion of the packaging signal has been deleted.
To generate the complementary viruses, plasmid GT5610 and viral DNA from AdH␤ were cotransfected in HepG2 cells by calcium phosphate precipitation (2 g of GT5610 plus 0.2 g of viral DNA per 1 ϫ 10 6 cells in 9.6-cm 2 wells). Medium was changed every other day, and the monolayer was monitored for the onset of plaques. To extract virions from cells, medium and cells were harvested and separated by centrifugation. Cells were lysed by two freeze/thaw cycles, and the cleared lysate was used to infect a fresh subconfluent monolayer of HepG2 cells. Viruses were purified in a CsCl gradient by ultracentrifugation and dialyzed against phosphate-buffered saline (PBS)/10% glycerol. Viral particle number was determined by optical density (1 OD 260 ϭ 10 12 particles). Viral titers in transducing units (TU) per mL were determined by infecting A549 cells with a serial dilution of the viral preparation and counting the number of green fluorescent cells or 5-bromo-4-chloro-3-indolyl ␤-D-galactoside (X-Gal)-stained cells, respectively, for GT5610 and AdH␤ at 24 hours postinfection. For restriction digest analysis, viral DNA was isolated from HepG2-infected cells by the spermine precipitation method.
13
HuH7 tumors in severe combined immunodeficient (SCID) mice SCID mice were obtained from Harlan Sprague-Dawley (Indianapolis, Ind). For cell-mixing experiments, HuH7 cells were infected at a multiplicity of infection (MOI) of 3 TU/cell with both GT5610 and AdH␤. After 2 days, infected cells were mixed with a 9-fold excess of uninfected cells. This mixture of cells as well as 100% infected and 100% uninfected cells were injected subcutaneously (s.c.) into the flanks of 8-week-old SCID mice (10 7 cells/100 L/site). For the treatment of established tumors, HuH7 cells were trypsinized, washed twice with PBS, and injected into both flanks of SCID mice (10 7 cells/100 L/site). When tumors reached ϳ500 mm 3 (2-3 weeks after cell injections), 20 l of control vehicle (PBS/10% glycerol) or complementary vectors (10 6 TU of both GT5610 and AdH␤) were injected directly into the tumors. In both experimental procedures, three mice (six tumors) were used for each group. Tumors were measured with a caliper at indicated times, and volume was estimated as (length ϫ width ϫ thickness)/2. Animal experiments were performed in accordance with institutional guidelines and approved by the Animal Use and Care Committee. Tumor volumes for the respective groups were compared using the Wilcoxon ranksum test (P Ͻ .01 was considered significant). For histological analysis, tumors were snap-frozen in cold isopentane, cryosectioned, and directly observed under fluorescence microscopy. Serial sections were processed for hematoxylin/eosin staining.
RESULTS AND DISCUSSION
The construction of the complementary vectors is based on a helper-dependent vector system described pre- The viral E1 region of Ad5 was replaced by a ␤-gal expression cassette in AdH␤. An E1 expression cassette containing the AFP promoter was inserted into GT5610. GT5610 also contains the GFP reporter gene and stuffer genomic sequences from the human albumin and AFP genes. After three passages in HepG2 cells, PshAI and NdeI were used to perform a restriction analysis of purified viral DNA. Dots indicate bands derived from AdH␤.
viously. 12 In an attempt to achieve sustained expression from adenoviral vectors, we constructed vectors without viral genes; these vectors contained only the minimal viral sequences for propagation (the ITRs necessary for viral replication and the packaging signal for encapsidation). The vectors were propagated in 293 cells by infection with an E1-deleted helper containing a partially deleted packaging signal. 12 In the present study, this vector system has been adapted for oncolysis by complementing the helper E1 deletion with E1 proteins expressed from the completely deleted vector. To confer selective replication in tumor cells, the E1A gene was placed under the control of the AFP promoter. Replication of both vectors requires the concurrent expression of the E1 proteins from the "controlled" vector and the rest of the viral genes from the "supplemental" vector. To test this dual viral system, we inserted the GFP reporter gene in the controlled vector and the ␤-gal reporter gene in the supplemental vector. The rest of the controlled vector genome is stuffer DNA derived from genomic sequences from the human albumin and AFP genes. This stuffer DNA increases the size of the vector for more efficient propagation. 12 The structures of the controlled and the supplemental vectors used in this study are shown in Figure 1 . Plasmid GT5610 was used to generate the GT5610 controlled vector. Plasmid and virus forms have the same structure, except that the plasmid is a circular molecule closed by a head-to-tail junction of the ITRs. To generate the virus, plasmid GT5610 was cotransfected in HepG2 cells (AFP-positive) together with viral DNA from the supplemental vector AdH␤. Evidence of complementation in the tumor cells was observed at 25 days after transfection by the spreading of a fluorescent plaque. In comparison with the generation of E1-deleted vectors in 293 cells, the time required for these plaques to appear is almost twice as long. This difference could be attributable to a faster and/or more productive propagation of Ad in 293 compared with HepG2, and also to a more efficient propagation of a single virus compared with two complementary defective viruses. When the cytopathic effect was complete, the virus mixture was extracted and propagated by infecting three times the number of HepG2 cells harvested. This ratio was chosen to allow the complete infection of the recipient cells (assessed by fluorescence microscopy at 24 hours postinfection). In these conditions, complete cytopathic effect was observed at 72 hours postinfection. At passage 3, both vectors were present in similar proportions, and the viral DNAs had the expected restriction patterns (Fig 1) . Virus purified from 1 ϫ 10 8 HepG2 cells yielded ϳ1 ϫ 10 9 TU of both vectors, with a bioactivity (TU/particles) of 0.01. This bioactivity is ϳ10 times lower than that obtained for single adenoviral vectors purified following similar protocols; however, it is consistent with that obtained for miniAd vectors. 12 The specificity of propagation was tested by infecting different AFP-positive or -negative cell lines and determining the cytopathic effects at different times postinfection. GT5610/AdH␤ produced a clear cytopathic effect at 3 days postinfection only in those hepatocarcinoma cells that express AFP (HepG2 and HuH7). Some rounding-up in cell shape was observed in the AFP-negative hepatocarcinoma cell line SK-Hep-1; although this effect was much less marked than in HepG2 and HuH7. We think that some leakage of the AFP promoter could explain this observation. This finding should be confirmed by sensitive expression assays. In general, if a tumor-specific promoter is not regulated tightly, a dual vector approach such as the one presented here would be safer than a single vector approach in terms of nonspecific viral replication. In the AFPnegative lung adenocarcinoma cells (A549), no cytopathic effect was observed for Յ15 days postinfection (Fig 2) .
To determine whether these complementary vectors would spread in vivo inside the tumor, we first compared the tumorigenicity of uninfected cells with that of mixtures of infected and uninfected cells in SCID mice ( Fig  3A) . Inoculation of 10 7 HuH7 cells (s.c.) gave rise to fast-growing tumors that were readily seen at day 16. The average size for these tumors at day 30 was 1776 Ϯ 650 mm 3 . Inoculation of a 1:9 mixture of infected to uninfected cells gave rise to slow-growing tumors with an average size of 685 Ϯ 430 mm 3 at day 30. In contrast, completely infected HuH7 cells were not able to develop tumors at all. Differences were significant at each timepoint (P Ͻ .01, Wilcoxon's sum of ranks). The fact that this kind of mixing experiment did not completely abrogate tumor growth could imply that higher amounts of both vectors need to be located in the same focus to start an efficient propagation inside the tumor. In that case, a single intratumoral (i.t.) injection of vector mixture could have a better outcome. To test this hypothesis and the oncolytic potential of these complementary Ads in a more clinically relevant model, we treated HuH7-established tumors by i.t. injection with purified vectors. If virus propagation occurs inside the tumor, therapeutic effects should be observed with much lower viral doses than with nonreplicating vectors. Therefore, we injected only 1 ϫ 10 6 TU, an amount that is 3-4 logs lower than that generally used to achieve therapeutic effects with replication-incompetent vectors. Figure 3B shows that the growth of the tumors treated with GT5610/AdH␤ was inhibited. At day 20, the average size of tumors injected with GT5610/AdH␤ was 151 mm 3 , as opposed to 591 mm 3 for untreated tumors (error bars represent the SE of the mean (SEM) (n ϭ 6, P Ͻ .01). However, we found a high degree of variability in tumor size in the former group (SD ϭ 185 mm 3 ).
Some tumors regressed completely, leaving only a scar in the original tumor site, whereas others grew to approximately half the size of the control group. Differences in sample injection because of physical features of the tumor such as shape or because of technical limitations could account for this variability. Another factor of variability could be the starting time of viral amplification, which in this system depends upon the probability of one cell being infected by both vectors. Injection with a higher titer vector mixture could help elucidate these possibilities. When sections of tumors treated with vehicle control or GT5610/AdH␤ were analyzed microscopically, large areas of necrosis were observed in both groups, with living cells surrounding blood vessels. In these fast-growing xenografts, the nutrient diffusion is limited; cells far apart from the vessel die. At day 15 postinjection, GT5610/AdH␤-treated tumors showed that ϳ40% of non-necrotic cells throughout the tumor transduced with the GFP transgene, indicating that viral replication had occurred inside the tumor. The areas of highest GFP concentration were located between the necrotic tissue and the living cells (Fig 4) . This pattern matches with the observed i.t. distribution of a single oncolytic virus 14 and suggests that the direction of viral propagation is from the necrotic tissue to the actively dividing cells closer to the blood vessel.
The final outcome of the oncolytic process will depend upon the relative propagation speed of the complementary vectors versus the tumor cells. The propagation speed is limited by the number of viruses produced per infected cell and could be increased using a wild-type packaging signal in the supplemental vector. In contrast to the nonreplicating miniAd vector system, 12 the use of a wild-type packaging signal for the controlled and supplemental vectors in this system would be appropriate, because the supplemental vector propagation depends upon the controlled vector and vice versa; one cannot outgrow the other. The use of wild-type packaging signal should increase the propagation efficiency of the complementary vectors and therefore the potency of the oncolysis. Although a single oncolytic vector may propagate more efficiently and therefore have more oncolytic potency, our dual vector system may prove useful if the transgenes are important for the oncolytic outcome. Tumor-suppressor, cytotoxic, and immunostimulatory genes could be used singly or in combination to enhance the oncolytic effect. For example, shifting the immune response toward a T helper 1 type could avoid the antibody blockage of viral spread and help to reject metastases. Transgenes such as the antigen costimulatory molecule B7 could elicit immune responses that have proven to be optimal when cytolysis is combined with immunostimulation. 15 Tumor cells transduced by only one of the complementary vectors would not be lysed until infected by the other vector, allowing the expression and presentation of these immunomodulatory molecules. The comparison of single and complementary replication-competent vectors for safety and efficacy in immunocompetent models that allow viral replication in normal cells will be crucial to find the best oncolytic vectors.
